Back to results
US 2026/0217716 A1Published application
Androgen receptor modulators and methods for their use
AssigneeCapulus Therapeutics, LLC
InventorsMichael John Green, Naveen Naganaboina, Ravikumar Muttineni, Sumana Ghosh
Life of this patent
Estimating the term…
Abstract
Androgen receptor modulators, and more particularly N-terminal domain androgen receptor inhibitors, comprising a heterocyclic bicyclic [1,2,4]triazolo[4,3-b]pyridazinyl ring core, as well as pharmaceutical compositions thereof are disclosed. Such compounds target the N-terminal domain (NTD) of the androgen receptor (AR) for treating cancers such as prostate cancer and specifically metastatic castration-resistant prostate cancer (mCRPC).
Claims20
A compound having a formula (I) or a pharmaceutically acceptable salt thereof:
- wherein
- R1 and R2 are independently a C1-C6 alkyl group optionally substituted with one or more fluorine or a C3-C6 cycloalkyl group optionally substituted with one or more fluorine;
- R3 is independently at each occurrence halogen, —CN, —OR5, —C(═O)R5, —NHC(═O)R5, —C(═O)NR5R6, —NR5R6, —P(—O)—R5R6, a C1-C6 alkyl group optionally substituted with one or more fluorine, or a C3-C6 cycloalkyl group optionally substituted with one or more fluorine;
- R4 is hydrogen or a C1-C6 alkyl group;
- R5 and R6 are independently at each occurrence hydrogen, a C1-C6 alkyl group, or
- R5 and R6 together with the nitrogen to which each is attached form a C3-C6 heterocycloalkyl group optionally substituted with one or more fluorine;
- and
- “n” is an integer from 1 to 5.
5 more elements
Dependencies are inferred from the claim text.